Crucell (CRXL) Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
More News related to CRXL
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- UBS Upgrades Crucell NV (CRXL) to Buy
- Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
- Calmune and Crucell Enter Exclusive Research Collaboration
- Crucell Announces Third Quarter 2009 Results
Dutch biopharmaceutical company Crucell N.V. (Nasdaq: CRXL) announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines.
Crucell has a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies to be used in association with a rabies vaccine for post-exposure prophylaxis against the fatal disease of rabies.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
